Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hepion Pharmaceuticals Inc | HEPA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.22 | 03:02:21 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.22 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.06 - 12.88 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.22 | USD |
Hepion Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.29M | 4.34M | - | 0 | -48.93M | -11.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Hepion Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEPA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.12 | 1.36 | 1.12 | 1.22 | 29,782 | 0.10 | 8.93% |
| 1 Month | 1.35 | 1.5499 | 1.06 | 1.22 | 37,082 | -0.13 | -9.63% |
| 3 Months | 2.12 | 2.8999 | 1.06 | 1.72 | 40,194 | -0.90 | -42.45% |
| 6 Months | 3.33 | 4.47 | 1.06 | 2.36 | 66,310 | -2.11 | -63.36% |
| 1 Year | 10.89 | 12.88 | 1.06 | 4.00 | 54,952 | -9.67 | -88.80% |
| 3 Years | 37.40 | 46.368 | 1.06 | 25.94 | 474,620 | -36.18 | -96.74% |
| 5 Years | 62.20 | 167.00 | 1.06 | 45.71 | 1,001,633 | -60.98 | -98.04% |
Hepion Pharmaceuticals Description
| Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. |
